Unifying CRM and EWOC designs for phase I cancer clinical trials

DOI10.1016/J.JSPI.2008.07.005MaRDI QIDQ1007501zbMATH OpenOpenAlexFDO

Authors Pei-Ling Chu, Yong Lin, Weichung Joe Shih

Publication date 20 March 2009

Published in Journal of Statistical Planning and Inference (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1016/j.jspi.2008.07.005

zbMATH Keywords

continual reassessment methodmaximum tolerated dosedose-limiting toxicityescalation with overdose controlphase I cancer clinical trial

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Recommendations

• Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
• Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials
• A class of designs for phase I cancer clinical trials combining Bayesian and likelihood approaches
• Continual reassessment and related dose-finding designs
• Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities

Cites work

• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Continual reassessment designs with early termination
• Design and Analysis of Phase I Clinical Trials
• Miscellanea. On sequential designs in nonlinear problems
• Non-parametric optimal design in dose finding studies
• Optimal Bayesian-feasible dose escalation for cancer phase I trials
• Prediction Approaches to Sequentially Searching for an Optimal Dose

Cited in

(8)

• A class of designs for phase I cancer clinical trials combining Bayesian and likelihood approaches
• PA‐CRM: A continuous reassessment method for pediatric phase I oncology trials with concurrent adult trials
• Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
• Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
• Bayesian dose escalation with overdose and underdose control utilizing all toxicities in phase I/II clinical trials
• Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies
• Adaptive clinical trial designs for phase I cancer studies
• Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials

Describes a project that uses

Uses Software

• EWOC

This page was built for publication: Unifying CRM and EWOC designs for phase I cancer clinical trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q1007501)